EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.

Neurology and Therapy, published by SPRINGER LONDON LTD, stands as a pivotal platform for researchers and practitioners in the field of neurology and its therapeutic applications. This Open Access journal, active since 2012, facilitates the dissemination of innovative studies and cutting-edge findings aimed at improving neurological health. With an impressive ranking in the 2023 Scopus Rankings, where it holds a Q2 category in Neurology and a Q1 category in Clinical Neurology, it underscores its prominence in advancing neurological research. The journal's intriguing scope encompasses a wide-ranging exploration of neurological disorders, treatment methodologies, and healthcare strategies, making it a valuable resource for those vested in enhancing patient outcomes. With an appealing average impact factor, readers are encouraged to dive into the latest advancements and engage with the scholarly discussions that are shaping the future of neurology.

Turkish Journal of Neurology, published by GALENOS PUBL HOUSE, is a pivotal open-access journal established in 2004, dedicated to advancing the field of neurology. Renowned for its inclusive approach, this journal serves as a vital platform for researchers and clinicians to share their findings and insights related to neurological disorders and clinical practices, with an emphasis on enhancing the understanding of various neurological conditions affecting populations in Turkey and beyond. Although it holds a Q4 rank in Neurology (Clinical) as per the 2023 category quartiles, the journal's commitment to fostering knowledge exchange remains steadfast, aiming to bridge gaps in clinical research and practice. With an ISSN of 1301-062X and an E-ISSN of 1309-2545, it is indexed in Scopus, ranking 349 out of 400, reflecting its growing presence in the academic sphere. Located in Istanbul, Turkey, the journal invites submissions from both emerging and established researchers to contribute to its diverse content, thereby enhancing its impact on the local and international neurology community.

Progress in Neurology and Psychiatry is a pivotal journal published by John Wiley & Sons Ltd, dedicated to advancing the fields of neurology and psychiatry. With a robust history dating back to its establishment, this esteemed journal holds a consistent Q3 ranking in 2023 across several categories including Neurology, Clinical Neurology, Psychiatry, and Mental Health, signifying its significant contribution to the scientific community. This journal serves as a vital source of knowledge and insight, publishing original research, reviews, and case studies that explore the intricacies of neurological and psychiatric disorders. Although it does not offer open access, the journal remains accessible to a wide audience through institutional subscriptions. By fostering a platform for scholarly discourse, Progress in Neurology and Psychiatry aims to bridge the gap between research and practice, ultimately enhancing the quality of care for individuals with neurological and psychiatric conditions. Researchers, clinicians, and students are encouraged to engage with the journal's comprehensive content to stay informed of the latest developments and emerging trends in these critical fields of medicine.

Annals of Clinical and Translational Neurology is a premier journal published by WILEY, focusing on the fields of neurology and neuroscience. Since its inception in 2014, it has established itself as an Open Access platform, providing unrestricted access to cutting-edge research to promote scientific collaboration and innovation. With an impressive Impact Factor residing in the top quartile (Q1) for both clinical neurology and miscellaneous neuroscience in 2023, this journal ranks #52 out of 400 in the Neurology category and #22 out of 113 in General Neuroscience, indicating its significant contribution to the field. The journal welcomes submissions that address emerging trends and challenges in translational neurology, aiming to bridge the gap between laboratory research and clinical practice. By disseminating high-quality research and fostering a community of scholars, Annals of Clinical and Translational Neurology plays a vital role in advancing our understanding of neurological disorders and improving patient care worldwide.

Multiple Sclerosis Journal, published by SAGE Publications Ltd, is a leading academic journal in the fields of neurology and clinical neurology, with an impressive impact factor reflecting its critical role in neurological research. Established in 1995 and continuing to 2024, this journal has positioned itself as a premier platform for disseminating innovative and impactful research related to multiple sclerosis, thereby contributing significantly to both clinical practice and scientific advancements in the field. The journal's robust standing is evidenced by its Q1 category rankings, placing it in the top tier of both Neuroscience (Rank #16/192, 91st Percentile) and Clinical Neurology (Rank #35/400, 91st Percentile) categories, making it an essential resource for researchers, healthcare professionals, and students alike. The journal focuses on a wide array of topics, including basic research, clinical trials, and treatment methodologies, ensuring that its readership is well-informed about the latest developments and trends. Access to its articles is through subscription, fostering a reputable environment for quality research dissemination.

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

The International Journal of Stroke, published by SAGE PUBLICATIONS LTD, is a leading peer-reviewed journal dedicated to advancing the field of stroke research and clinical practice. Established with a commitment to disseminating high-quality scholarly articles, this journal has rapidly progressed to achieve a prestigious Q1 ranking in both Neurology and Clinical Neurology categories as of 2023. With a remarkably high Scopus rank of #7 among 192 in Neuroscience and #16 among 400 in Clinical Neurology, it places itself firmly in the top 4% of journals in its field, reflecting its significant impact on the academic and clinical landscape. Although it does not currently offer Open Access options, the journal provides a vital platform for researchers and clinicians alike, focusing on innovative treatments, methodologies, and evolving strategies for stroke prevention and recovery. With a publication scope that spans from 2006 to 2024, the International Journal of Stroke continues to foster knowledge exchange and encourage collaboration, making it an essential resource for anyone involved in neurologic healthcare.

The Lancet Neurology is a premier academic journal published by Elsevier Science Inc, specializing in the field of neurology. With a robust impact factor that signifies its authoritative presence, it consistently ranks in the Q1 category for clinical neurology according to the 2023 standards, positioning itself as the leading journal in its domain, ranking #1 out of 400 in Scopus' neurology rankings and placing in the 99th percentile. Since its establishment in 2002, it has provided a vital platform for disseminating innovative research and clinical advances related to neurological disorders. The journal’s precise focus includes cutting-edge studies on neurodegenerative diseases, stroke, epilepsy, and neuroimaging, which are essential for advancing clinical practice and improving patient outcomes. While it does not offer open access, readers can find high-impact research published monthly, making it indispensable for practitioners, researchers, and students eager to stay at the forefront of neurological science.

Multiple Sclerosis Journal-Experimental Translational and Clinical, published by SAGE Publications, Inc., is an essential open-access platform since 2015 dedicated to advancing research in the field of multiple sclerosis and related neurological disorders. With an ISSN of N/A and an E-ISSN of 2055-2173, the journal aims to bridge the gap between experimental studies and clinical applications, offering valuable insights into cellular and molecular neuroscience as well as clinical neurology. The journal holds a reputable Q3 ranking in Cellular and Molecular Neuroscience and a Q2 ranking in Neurology (Clinical) for 2023, indicating its significant contribution to these fields. Positioned at the intersection of scientific discovery and clinical practice, the Multiple Sclerosis Journal serves as an indispensable resource for researchers, clinicians, and students dedicated to improving outcomes for individuals affected by multiple sclerosis and related disorders. With a Scopus ranking of #163/400 in Medicine - Neurology and #67/97 in Neuroscience, this journal continues to play a pivotal role in shaping the future of neurological research and therapy.